Stop Ozempic? New Study Reveals Surprising Weight Recovery Results After GLP-1

Since millions of people use injectable GLP-1 medications like Ozempic, Wegovy, or Zepbound, many may wonder what happens if they stop.

Previous clinical trials suggested a disappointing “rebound” effect, in which patients regained a significant portion of their lost weight almost immediately after completing treatment.

However, a new study from the Cleveland Clinic, published in the journal Diabetes, Obesity and Metabolism, offers a more hopeful perspective on what happens when the injections stop.

A SPECIFIC AMOUNT OF NIGHTTIME SLEEP MAY REDUCE THE RISK OF DIABETES, RESEARCHERS FIND

The study examined nearly 8,000 adults in Ohio and Florida who used semaglutide or tirzepatide for three to 12 months before stopping, according to a news release.

Unlike strictly controlled clinical trials, the researchers looked at “real-world” results in which patients often switch from one medication to another.

Overall, patients did not experience significant weight regain in the year after stopping GLP-1. Among those treated specifically for obesity, the average weight loss before discontinuation was 8.4%; a year later, they had recovered only 0.5% on average.

“Our real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials,” the study’s lead author, Dr. Hamlet Gasoyan, said in the news release.

NEW WEGOVY PILL OFFERS NEEDLE-FREE WEIGHT LOSS, BUT MAY NOT WORK FOR EVERYONE

This suggests that the rebound seen in clinical trials may be a result of patients being left without alternative support, a scenario that does not have to occur in clinical practice, the researchers say.

An estimated 27% of patients transitioned to different medications, including older generation obesity medications, while another 20% eventually restarted their original medication once insurance issues or side effects were resolved.

Another 14% transitioned to intensive lifestyle modification programs, working closely with dietitians and exercise specialists.

CLICK HERE FOR MORE HEALTH STORIES

Patients who maintained their weight tended to remain engaged with the health care system, whether through alternative prescriptions or structured lifestyle support, the researchers noted.

CLICK HERE TO SUBSCRIBE TO OUR HEALTH NEWSLETTER

There were some limitations to the study.

“We included adult patients from a single large integrated health system in Ohio and Florida,” the authors noted. “Patient characteristics and health care delivery patterns vary across the US, which may limit the generalizability of our findings.”

Some of the observed weight reduction may be associated with other interventions that the researchers were unable to capture.

TRY OUR LATEST LIFESTYLE QUIZ

“In our future work, we will examine the comparative effectiveness of alternative treatment options for obesity in patients who discontinue treatment with semaglutide or tirzepatide, to help patients and their physicians make informed decisions,” Gasoyan added.